Drug Profile
Long acting programmed death ligand 1 - Genexine
Alternative Names: GX-P2Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Genexine
- Class Anti-inflammatories; Antipsoriatics; Recombinant fusion proteins
- Mechanism of Action Programmed cell death-1 ligand-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases; Psoriasis
Most Recent Events
- 19 May 2020 No development reported - Preclinical for Inflammatory bowel diseases in South Korea (Parenteral)
- 19 May 2020 No development reported - Preclinical for Psoriasis in South Korea (Parenteral)
- 06 May 2016 Preclinical trials in Psoriasis in South Korea (Parenteral) before May 2016